QuidelOrtho Corp (NASDAQ: QDEL)

QuidelOrtho Corp, also known as QDEL, is a leading global diagnostics company that operates in the healthcare industry. Its primary business activities involve the design, development, manufacturing, and marketing of diagnostic testing solutions for a wide range of diseases and conditions. These solutions cater to various medical fields, including infectious diseases, cardiovascular disease, oncology, and reproductive health. The company's operations span across the globe, with manufacturing facilities in the U.S. and U.K., and sales centers, administrative offices, and warehouses located in numerous countries and territories.

QuidelOrtho Corp generates revenue through its four business units: Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics. The Labs business unit offers clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients. The immunodiagnostics products, such as Sofia and Sofia 2, use lateral-flow technology and advanced fluorescent immunoassay chemistry to provide rapid and accurate test results.

The Transfusion Medicine business unit provides immunohematology instruments and tests that aid in blood typing and antibody identification, helping confirm patient-donor compatibility in blood transfusions. The ORTHO VISION platform is a flagship immunohematology analyzer that automates blood typing, antibody identification, and crossmatching for patient and donor blood banks.

The Point of Care business unit offers rapid immunoassay products, such as Sofia and Sofia 2, which use lateral-flow technology and advanced fluorescent immunoassay chemistry to provide quick and accurate test results. The QuickVue products are a broad portfolio of rapid, visually read, lateral flow immunoassay products that diagnose a wide variety of infectious diseases and medical conditions.

The Molecular Diagnostics business unit provides tests for polymerase chain reaction (PCR) thermocyclers with reduced process time and ready-to-use reagent configurations. The Savanna platform is a simplified molecular testing platform that uses proprietary isothermal helicase-dependent amplification technology to provide easy-to-use and high-throughput testing solutions.

QuidelOrtho's competitive strengths lie in its superior customer experience and brand loyalty, innovation and research and development capabilities, operational scale driven by investments in U.S. manufacturing capabilities and an extensive and balanced global commercial footprint, and a leadership team dedicated to preserving a culture of continuous improvement and employee happiness.

The company's business strategy revolves around transforming diagnostics into action for more people in more places. With a focus on investing in research and development, QuidelOrtho aims to offer a broader test menu to more care settings for more patients. The company also leverages its large and growing installed base of instruments in both laboratories and point-of-care settings to drive laboratory automation and efficiency, improve access to new and novel diagnostics, and enable patients and providers to experience the full benefits of a remote and digitized healthcare system.

In terms of brand names and trade names, QuidelOrtho has several notable products. These include the Sofia and Sofia 2 immunodiagnostics products, the ORTHO VISION immunohematology analyzer, the QuickVue rapid immunoassay products, and the Savanna molecular testing platform.